Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-12-16 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思2025年第三次临时股东会资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2025 Third Extraordinary General Meeting of Shareholders" of Hangzhou Anjiesi Medical Technology Co., Ltd. It includes detailed meeting instructions, agenda, and a specific proposal regarding changes to the company's registered capital and amendments to the Articles of Association. The content is focused on the meeting procedures, voting rights, and the agenda items to be discussed and voted on during the shareholders' meeting. There is no financial data or report analysis present, but rather it is a set of meeting materials prepared for the shareholders' meeting. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or other shareholder meetings. The document length is about 4043 characters, which is consistent with a meeting material document rather than a full report or announcement of results. Therefore, the correct classification is AGM Information (AGM-R).
2025-12-16 Chinese
安杰思关于召开2025年第三季度业绩说明会的公告
Investor Presentation Classification · 85% confidence The document is an announcement about the scheduling and details of a 2025 third quarter earnings explanation meeting (业绩说明会), including the date, time, location, participants, and how investors can participate and ask questions. It references the previously released 2025 third quarter report but does not contain any financial data or results itself. The document is short (1462 characters) and serves to inform investors about the upcoming earnings call rather than presenting financial results or detailed analysis. Therefore, it is best classified as a Call Transcript announcement or related to an earnings call event. However, since it is only an announcement of the meeting and not the transcript itself, the closest fitting category is Investor Presentation (IP) or possibly Regulatory Filings (RNS). Given the detailed description of the meeting and investor interaction, the best fit is Investor Presentation (IP).
2025-12-08 Chinese
安杰思关于变更公司注册资本并修订《公司章程》的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the change in the company's registered capital and the corresponding amendment to the company's articles of association (公司章程). It details the increase in registered capital due to the completion of a restricted stock incentive plan and the related share registration. The document also mentions that the amendment to the articles will be submitted to the shareholders' meeting for approval and that the final change is subject to regulatory approval. The document is relatively short (1042 characters) and serves as a formal announcement of these corporate changes rather than a full report or detailed financial statement. It does not contain comprehensive financial data or detailed management discussion, nor is it a report of voting results or a proxy solicitation. It is a regulatory announcement about capital change and corporate governance document amendment. According to the filing definitions, announcements about changes in registered capital and amendments to the articles of association fall under Share Issue/Capital Change (SHA). Therefore, the appropriate classification is SHA with high confidence.
2025-12-08 Chinese
安杰思公司章程
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association for Hangzhou AGS MedTech Co Ltd, covering company structure, shareholder rights, board and management roles, share issuance, share transfers, shareholder meetings, and governance rules. It references Chinese company law, securities law, and regulatory requirements. The content is about the internal governance framework, shareholder meetings, board responsibilities, and related corporate governance matters. There is no indication that this is an annual report, earnings release, or any financial statement. It is not a proxy solicitation or voting results announcement, nor a call transcript or capital update. The document is a governance document detailing the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR). The document length and detail confirm it is the actual governance document, not just an announcement or summary.
2025-12-08 Chinese
安杰思关于召开2025年第三次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2025 third extraordinary general meeting of shareholders for Hangzhou Anjiesi Medical Technology Co., Ltd. It includes information about the meeting date, voting methods, agenda items, registration procedures, and proxy authorization. There is no financial data or report content, but rather an announcement and instructions related to a shareholders' meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is 3217 characters, which is consistent with a detailed meeting notice rather than a full report. Therefore, the correct classification is PSI with high confidence.
2025-12-08 Chinese
安杰思2025年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 Third Quarter Report" of Hangzhou Anjiesi Medical Technology Co., Ltd. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the third quarter period ending September 30, 2025. The report explicitly states it is unaudited and covers a quarterly period (3 months). It includes comprehensive financial statements and analysis of financial indicators, which is characteristic of an Interim / Quarterly Report. There is no indication that this is an announcement of a report or a certification document. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-27 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.